OIS Podcast | Ophthalmology's leading Podcast

After being honored by OIS last week in Chicago with an OIS Innovator Award, David Pyott, former Allergan CEO, sits down with OIS-TV to discuss rebuilding Allergan, fending off Valeant’s acquisition bid, and how he feels about the acquisition by Actavis. He also reviews the work he’s doing with start-ups and global charities.

This OIS Podcast brings a bit of OIS@AAO to your laptop and smartphone. Hear from a few of the leaders in ophthalmology including executives from Allegro Ophthalmics, Avedro, LacriScience, Ocular Therapeutics, Opthea, and Sightline Surgical.

OIS has partnered with Michael Lachman of EyeQ Research to create a vital new stock index of ophthalmology companies. This new tool will enable us to deliver broader insights and stronger analysis of our exciting sector.

Emmett T. Cunningham Jr., MD, PhD, MPH, partner at Clarus, runs through the revamped agenda of OIS@AAO. Go to OIS.net to view the agenda and to register.

This month, a surgeon performed ophthalmology’s first robot-assisted surgery – a membrane peel. Prof. Marc de Smet, chief medical officer of Preceyes, a Dutch start-up shares the company’s history and plans for the future.

Ashley McEvoy, group chairman of J&J’s Vision Group, says the combination of consumer and surgical businesses will create a powerful new force in ophthalmology.

Copenhagen was the epicenter of the ophthalmology last week as several clinical meetings including ESCRS, EuRetina, and EuCornea convened in the city. OIS Podcast reports from the hallways, meeting spaces, and exhibition floor.

Shire scored a huge win this summer by securing FDA approval of Xiidra. Hear from three principals of SARcode Bioscience, the start-up that discovered the Dry Eye treatment – then known as lifitegrast.

OIS Podcast hit the century mark. Rather than offer a retrospective piece, we hope you enjoy this thoughtful look forward as we ask physicians, executives, investors, and others what is to come in ophthalmology innovation.

ReVision Optics built it – a corneal inlay capable of correcting presbyopia. The FDA approved it sooner than expected. Now the company needs to build it into a successful private-pay business.

Live from the floor of OIS@ASRS: Co-chair Bill Link on what made the day work so well. The marriage of OIS with ASRS started strong. Hear ophthalmology veteran Bill Link on why the back of the eye is an enormous opportunity for companies, investors, and physicians.

Meet the newest Master of the Industry. Jim Mazzo, who has led divisions, spin-outs, and start-ups, now leads what looks to be a new leader in ophthalmology. Hear how Mazzo views this new opportunity for Zeiss and himself.

Clearside CEO Dan White says the days when ophthalmology IPO candidates could do no wrong are over. Still, the company staged a successful IPO to help further development of its SCS microinjector technology.

Allegro Ophthalmics’ executive team boasts a successful pedigree that began with starting ISTA and taking it public. Now, Vicken Karageozian, MD, president and CMO, says the company is six months away from receiving results from Phase II trials. Hear how the firm has advanced this promising new drug without venture capital.

Robert Dempsey joined Shire to build a new ophthalmology unit. Until now, the division had been mostly theoretical with no products to sell. Now, the brand building is over. Shire officially has entered the ophthalmology sector with the launch of its potential blockbuster, Xiidra. Hear what’s next for the Dry Eye treatment and what else we can expect to see from Shire’s pipeline.

Over two decades ago, Mark Humayun - who will co-chair our upcoming OIS@ASRS - helped launch a “moonshot” that would eventually restore vision for retinitis pigmentosa patients. In this podcast we discuss what drives him and what’s next for ophthalmology.

Pfizer. Allergan. Valeant. Bausch & Lomb. The ophthalmology sector is rich in big deals that happened, didn’t happen, and could happen. How does the sector – and the market overall – look to analysts?

Steven Vold, MD, sees huge advances in MIGs treatment, drug delivery and new neuroprotective compounds that could help treat glaucoma and perfect vision.

Once a VC, Todd Barry decided to assume the CEO and president post of Aldeyra, a start-up with a promising – and potentially far-reaching – technology for treating ocular and other diseases.

Dr. Ludwin Monz, president and CEO of Carl Zeiss Meditec AG, shares how his company’s long history in ophthalmology helps it pave a path for new markets and technologies.

Bausch & Lomb’s chief medical officer Calvin Roberts, MD, still thinks like a doc when he’s helping to steer the company’s strategy. Hear how he sees B&L making life simpler for ophthalmologists in the near future.

Robert Dempsey, vice president of ophthalmics at Shire, was charged with building a brand in ophthalmology with no new drugs. Two years later, Shire has – in the words of one physician – one of “the best kept secrets” in eye care. Dempsey explains how Shire came to build something from nothing.

Deals sometime collapse, but they usually don’t get hit with a smart bomb from the Department of Treasury. Allergan, newly single following the break up with Pfizer, is looking to build a business in ophthalmology. Bill Meury, the newly named chief commercial officer of Allergan, talks about the non-Pfizer deal, Allergan’s ophthalmology pipeline and where the acquisitive company will be looking fo...

The fifth OIS@ASCRS delivered highlights on diagnostics, glaucoma devices, and What The Future of ophthalmology might bring. OIS Podcasts will provide a quick review of the day for those who couldn’t make it (or simply had overstuffed their meeting calendar in New Orleans).